Korea Business News Agency - NSP NEWS AGENCY.

fullscreen

(Seoul=NSP NEWS) = Samyang Biopharm, the pharmaceutical and biotechnology subsidiary of South Korea’s Samyang Group, was listed on the Kospi on the 24th, marking its official debut on the nation’s main bourse. The company issued a total of 7,435,870 shares. Its stock quickly hit the upper price limit shortly after the market opened, trading at 30,200 won—up 29.89 percent, or 6,950 won, from its initial listing price of 23,250 won.

The listing follows a spinoff earlier this month, when Samyang Holdings—the group’s parent company—separated the biopharmaceutical unit through a physical division and pursued a direct listing. The move is expected to give Samyang Biopharm easier access to capital for research and development as well as for its global expansion efforts.

Samyang Biopharm plans to build corporate value around its portfolio of specialty products, including biodegradable surgical sutures, gene delivery systems, and anticancer transporters.

“Through this listing, our technological capabilities and growth potential can now be evaluated independently,” CEO Kim Kyung-jin said. “We aim to enhance our corporate value by leveraging our competitive strengths, ultimately contributing to the broader valuation of the Samyang Group.”

By Eun-young Huh(eunyoung114@nspna.com) and Songyi Jeong(qu225577@nspna.com)

ⓒNSP News Agency·NSP TV. All rights reserved. Prohibits using to train AI models.